With focus on inflammation and pain

Key strength No.1

Unique and protected technology platform

Key strength No.1

Unique mode of action

Unique mode of action –
5-HT2 receptor antagonism.

Unique platform

Unique platform with four different chemical classes.

Unique stability

Unique stability – financial and organisational.

Phase II

AMAP102 has successfully completed Phase I. The Phase II trial is now recruiting patients.

News News

New share issue completed.
AnaMar raised 45 MSEK.